Value of Deoxyribonucleic Acid Ploidy and Nuclear Morphometry for Prediction of Disease Progression in Renal Cell Carcinoma-Reference-Cited by-同舟云学术

Value of Deoxyribonucleic Acid Ploidy and Nuclear Morphometry for Prediction of Disease Progression in Renal Cell Carcinoma

Published:1996-02 Issue:2 Volume:155 Page:459-465
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

Ruiz-Cerda Jose L.¹,Hernandez Miguel¹,Gomis Federico¹,Vera Cesar D.¹,Kimler Bruce F.¹,O'Connor J. Enrique¹,Jimenez-Cruz Fernando¹

Affiliation:

1. Departments of Urology, Pathology and Hematology, La Fe University Hospital and Flow Cytometry Reference Center, Faculty of Medicine, University of Valencia, Valencia, Spain, and Department of Radiation Oncology, University of Kansas Medical Center, Kansas City, Kansas.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference26 articles.

1. Clinical Flow Cytometry: Principles and Applications;Bauer,1993

2. Urological cancers;Shankey,1993

3. Nuclear morphometry as an important prognostic factor in stage I renal cell carcinoma;Tosi;Cancer,1986

4. Nuclear shape analysis for assessment of prognosis in renal cell carcinoma;Murphy;J. Urol.,1990

5. Nuclear morphometry in prognosis of renal adenocarcinoma;Gutierrez;Urology,1992

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A non-diploid DNA status is linked to poor prognosis in renal cell cancer;World Journal of Urology;2020-05-02

2. Intracellular PK/PD Relationships of Free and Liposomal Doxorubicin: Quantitative Analyses and PK/PD Modeling;Molecular Pharmaceutics;2016-03-16

3. In vivo Aneuploidization during the Expansion of Renal Adenocarcinoma;Urologia Internationalis;2011

4. Análisis de los factores pronósticos de progresión tumoral en el adenocarcinoma renal;Actas Urológicas Españolas;2007-01

5. Nonmetastatic renal-cell carcinoma: is it really possible to define rational guidelines for post-treatment follow-up?;Nature Clinical Practice Oncology;2006-04